Drug Profile


Alternative Names: Actos; AD-4833; Glustin; PGZ; Piozone; U 72107; U 72107A; U 72107E; Zactos

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Duke University Medical Center; Eli Lilly; Glenmark Pharmaceuticals Ltd; Novo Nordisk; Piramal Enterprises; Takeda; Takeda Pharmaceuticals USA; Tianjin Takeda; Zinfandel Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Alzheimer's disease
  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Atherosclerosis; Multiple sclerosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2016 Takeda and Zinfandel Pharmaceuticals complete enrolment in the phase III TOMMORROW trial in Alzheimer's disease in USA, the United Kingdom, Germany, Switzerland and Australia
  • 11 Sep 2015 Registered for Type-2 diabetes mellitus in Russia, Brazil, Australia prior to September 2015 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top